Download PDF
Horm Metab Res 2012; 44(05): 373-378
DOI: 10.1055/s-0032-1306275
Review
© Georg Thieme Verlag KG Stuttgart · New York

Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art?

M. Mannelli
1   Department of Clinical Pathophysiology, University of Florence, Florence, Italy
,
H. Dralle
2   Department of General, Visceral and Vascular Surgery, University of Halle-Wittemberg, Halle/Saale, Germany
,
J.W. M. Lenders
3   Department of Medicine, Division of General Internal Medicine, Radboud Adrenal Centre, University Nijmegen Medical Centre, Nijmegen, The Netherlands
4   Department of Medicine III, Carl Gustav Carus University Medical Centre, Dresden, Germany
› Author Affiliations
Further Information

Publication History

received 14 November 2011

accepted 08 February 2012

Publication Date:
19 April 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Pheochromocytoma and paraganglioma are rare tumors of sympathetic or parasympathetic origin, presenting with a highly variable clinical picture. Rarity, as well as biological, clinical, and genetic heterogeneity are barriers to initiate prospective studies that help to establish clinical guidelines. The best management of these patients relies on the experience of a multidisciplinary team. The ultimate outcome can benefit from adequate pre-surgical evaluation and treatment as well as an accurate post-surgical follow-up. Long-term follow-up is mandatory in all patients, but is particularly important in specific familial cases such as those with an SDHB mutation where the risks of recurrence are higher. The surgical approach varies depending on tumor size, location, and surgeon’s personal attitude and experience. In this paper, we summarize recommendations, based mostly on authors’ and other experts’ personal experiences, for the best possible management of patients prior, during and after surgery, as well as when pheochromocytoma is diagnosed during pregnancy.

Key words

pheochromocytoma - anesthesia - surgery - pregnancy
 

  • References

  • 1 Manger WM, Gifford Jr RW. Clinical and experimental pheochromocytoma. Cambridge, MA: Blackwell Science; 1996
    Google Scholar
  • 2 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665-675
    CrossrefPubMedGoogle Scholar
  • 3 Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147: 1-10
    PubMedGoogle Scholar
  • 4 Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134: 315-329
    CrossrefPubMedGoogle Scholar
  • 5 Kuhwaide R, Lanser MJ, Fish U. Cathecolamine-secreting paragangliomas of the skull base. Skull Base Surg 1996; 6: 35-45
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, Smit JW, Romijn JA, Corssmit EP. Increased Urinary Excretion of 3-methoxytyramine in Patients with Head and Neck Paragangliomas. J Clin Endocrinol Metab 2010; 95: 209-214
    CrossrefPubMedGoogle Scholar
  • 7 Jafri M, Maher E. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol 2012; 166: 151-158
    CrossrefPubMedGoogle Scholar
  • 8 Manger WM. The protean manifestations of pheochromocytoma. Horm Met Res 2009; 41: 658-663
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Liao WB, Liu CF, Chiang CW, Kung CT, Lee CW. Cardiovascular manifestations of pheochromocytoma. Am J Emerg Med 2000; 18: 622-625
    CrossrefPubMedGoogle Scholar
  • 10 Shao Y, Chen R, Shen ZJ, Teng Y, Huang P, Rui WB, Xie X, Zhou WL. Preoperative alpha-blockade for pheochromocytoma: is it necessary?. J Hypertens 2011; 29: 2429-2432
    CrossrefPubMedGoogle Scholar
  • 11 Bravo EL. Pheochromocytoma. Curr Ther endocrinol Metab 1997; 6: 195-197
    PubMedGoogle Scholar
  • 12 James MFM, Cronje L. Pheochromocytoma Crisis: The use of Magnesium Sulfate. Anesth Analg 2004; 99: 680-686
    CrossrefPubMedGoogle Scholar
  • 13 Steinsapir J, Carr AA, Prisant LM, Bransome Jr ED. Metyrosine and pheochromocytoma. Arch Int Med 1997; 157: 901-906
    CrossrefPubMedGoogle Scholar
  • 14 Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with pheochromocytoma. Drug safety 2007; 30: 1031-1062
    CrossrefPubMedGoogle Scholar
  • 15 Desmonts JM, Marty J. Anaesthetic management of patients with phaeochromocytoma. Br J Anaesth 1984; 56: 781-789
    CrossrefPubMedGoogle Scholar
  • 16 Walz MK, Alesina PF, Wenger FA, Koch JA, Neumann HP, Petersenn S, Schmid KW, Mann K. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg 2006; 30: 899-908
    CrossrefPubMedGoogle Scholar
  • 17 Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007; 92: 1217-1225
    CrossrefPubMedGoogle Scholar
  • 18 Burnichon N, Rohmer V, Amar L, Hermann P, Leboulleux S, Darrouzet V, Niccoli P, Gaillard D, Chabrier G, Chabolle F, Coupier I, Thieblot P, Lecomte P, Bertherat J, Wion-Barbot N, Murat A, Venisse A, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009; 94: 2817-2827
    CrossrefPubMedGoogle Scholar
  • 19 Hermsen MA, Sevilla MA, Llorente JL, Weiss MM, Grimbergen A, Allonca E, Garcia-Inclan C, Balbin M, Suarez C. Relevance of germline mutation screening in both familial and sporadic head and neck paraganglioma for early diagnosis and clinical management. Cellular Oncology 2010; 32: 275-283
    PubMedGoogle Scholar
  • 20 Hu K, Persky MS. Multidisciplinary management of paragangliomas of the head and neck, part 1. Oncology 2003; 17: 983-993
    PubMedGoogle Scholar
  • 21 Hu K, Persky MS. The multidisciplinary management of paragangliomas of the head and neck, part 2. Oncology 2003; 17: 1143-1153
    PubMedGoogle Scholar
  • 22 Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg 2004; 91: 1259-1274
    CrossrefPubMedGoogle Scholar
  • 23 Toniato A, Boschin IM, Opocher G, Guolo A, Pelizzo M, Mantero F. Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment?. Surgery 2007; 141: 723-727
    CrossrefPubMedGoogle Scholar
  • 24 Guerrero MA, Schreinemakers JMJ, Vriens MR, Suh I, Hwang J, Shen WT, Gosnell J, Clark OH, Duh QY. Clinical spectrum of pheochromocytoma. J Am Coll Surg 2009; 209: 727-732
    CrossrefPubMedGoogle Scholar
  • 25 Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 2004; 136: 1129-1137
    CrossrefPubMedGoogle Scholar
  • 26 Henry JF, Sebag F, Iacobone M, Mirallie E. Results of laparoscopic adrenalectomy for large and potentially malignant tumors. World J Surg 2002; 26: 1043-1047
    CrossrefPubMedGoogle Scholar
  • 27 Walz MK, Peitgen K, Diesing D, Petersenn S, Janssen EO, Philipp T, Metz KA, Mann K, Schmid KW, Neumann HPH. Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasia. World J Surg 2004; 28: 1323-1329
    CrossrefPubMedGoogle Scholar
  • 28 Walz MK, Alesina PF, Wenger FA, Deligiannis A, Szuczik E, Petersenn S, Ommer A, Groeben H, Peitgen K, Janssen OE, Philipp T, Neumann HPH, Schmid KW, Mann K. Posterior retroperitoneoscopic adrenalectomy – results of 560 procedures in 520 patients. Surgery 2006; 140: 943-950
    CrossrefPubMedGoogle Scholar
  • 29 Berber E, Tellioglu G, Harvey A, Mitchell J, Milas M, Siperstein A. Comparison of laparoscopic transabdominal lateral versus posterior retroperitoneal adrenalectomy. Surgery 2009; 146: 621-626
    CrossrefPubMedGoogle Scholar
  • 30 Evans DB, Perrier ND. Invited commentary: on “posterior retroperitoneoscopic adrenalectomy – results of 560 procedures in 520 patients”. Surgery 2006; 140: 951-952
    CrossrefPubMedGoogle Scholar
  • 31 Walz MK, Peitgen K, Neumann HPH, Janssen OE, Philipp T, Mann K. Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg 2002; 26: 1005-1012
    CrossrefPubMedGoogle Scholar
  • 32 Dralle H, Scheumann GFW, Kotzerke J, Brabant EG. Surgical management of MEN2. Rec Res Cancer Res 1992; 125: 167-195
    PubMedGoogle Scholar
  • 33 Walz MK, Peitgen K, Saller B, Giebler RM, Lederbogen S, Nimtz K, Mann K, Eigler FW. Subtotal adrenalectomy by the posterior retroperitoneoscopic approach. World J Surg 1998; 22: 621-627
    CrossrefPubMedGoogle Scholar
  • 34 Brauckhoff M, Gimm O, Thanh PN, Bär A, Ukkat J, Brauckhoff K, Bönsch T, Dralle H. Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery 2003; 134: 1020-1028
    CrossrefPubMedGoogle Scholar
  • 35 Brauckhoff M, Stock K, Stock S, Lorenz K, Sekulla C, Brauckhoff K, Thanh PN, Gimm O, Spielmann RP, Dralle H. Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. World J Surg 2008; 32: 863-872
    CrossrefPubMedGoogle Scholar
  • 36 Telenius-Berg M, Ponder MA, Berg B, Ponder BAJ, Werner S. Quality of life after bilateral adrenalectomy in MEN2. Henry Ford Hosp Med J 1989; 37: 160-163
    PubMedGoogle Scholar
  • 37 Machens A, Brauckhoff M, Holzhausen HJ, Thanh NP, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005; 90: 3999-4003
    CrossrefPubMedGoogle Scholar
  • 38 Paris J, Facon F, Thomassin JM Zanaret Cervical paragangliomas: neurovascular surgical risk and therapeutic management. Eur Arch Otohinolaryngol 2006; 263: 860-865
    PubMedGoogle Scholar
  • 39 Papaspyrou K, Mann WJ, Amedee RG. Management of head and neck paragangliomas: review of 120 patients. Head Neck 2009; 31: 381-387
    CrossrefPubMedGoogle Scholar
  • 40 Netterville JL, Reilly KM, Robertson D, Reiber ME, Armstrong WB, Childs P. Carotid body tumors: a review of 30 patients with 46 tumors. Laryngoscope 1995; 105: 115-126
    CrossrefPubMedGoogle Scholar
  • 41 Linder F. Tumoren der Carotisdrüse. Langenbecks Arch Dtsch Z Chir 1953; 276: 156-161
    PubMedGoogle Scholar
  • 42 Shamblin WR, ReMine WH, Sheps SG, Harrison EG. Carotid Body Tumor (Chemodectoma). Am J Surg 1971; 122: 732-739
    CrossrefPubMedGoogle Scholar
  • 43 Siedek V, Waggershauser T, Berghaus A, Matthias C. Intraoperative monitoring of intraarterial paraganglioma embolization by indocyaningreen fluorescence angiography. Eur Arch Otorhinolaryngol 2009; 266: 1449-1454
    CrossrefPubMedGoogle Scholar
  • 44 Hinermann RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM. Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck 2008; 30: 1431-1438
    CrossrefPubMedGoogle Scholar
  • 45 O’Riordan JA. Pheochromocytomas and anesthesia. Int Anesthesiol Clin 1997; 35: 99-127
    PubMedGoogle Scholar
  • 46 Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 29: 1133-1139
    CrossrefPubMedGoogle Scholar
  • 47 Lenders JWM. Pheochromocytoma and pregnancy: a deceptive connection. Eur J Endocrinol 2012; 166: 143-150
    CrossrefPubMedGoogle Scholar